Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Evaluation of complement proteins as screening markers for colorectal cancer

Research output: Contribution to journalJournal articleResearchpeer-review

  1. In vitro 4-1BB stimulation promotes expansion of CD8+ tumor-infiltrating lymphocytes from various sarcoma subtypes

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. NY-ESO-1- and survivin-specific T-cell responses in the peripheral blood from patients with glioma

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Efficient tumor cell lysis mediated by a Bcl-X(L) specific T cell clone isolated from a breast cancer patient

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Noncoding RNA (ncRNA) Profile Association with Patient Outcome in Epithelial Ovarian Cancer Cases

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Prognostic utility of serum YKL-40 in patients with cervical cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Helicobacter pylori Colonization Drives Urokinase Receptor (uPAR) Expression in Murine Gastric Epithelium During Early Pathogenesis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Line Storm
  • Ib J Christensen
  • Jens C Jensenius
  • Hans J Nielsen
  • Steffen Thiel
  • the Danish Study Group on Early Detection of Colorectal Cancer
  • Lars Nannestad Jørgensen
  • Jesper Vilandt
  • Thore Hillig
View graph of relations

BACKGROUND: Colorectal cancer (CRC) is a leading cause of cancer death worldwide. Lack of symptoms results in late detection and increased mortality. Inflammation, including complement activation, plays an important role in tumorigenesis.

EXPERIMENTAL DESIGN: The concentrations of nine proteins of the lectin pathway of the complement system were determined using time-resolved immunofluorometric assays. The first cohort investigated comprised a matched case-control study of 95 patients with CRC, 48 patients with adenomas and 48 individuals without neoplastic findings. Based on the results, Collectin-liver 1 (CL-L1), M-ficolin and MAp44 were determined as the most promising biomarkers and were subsequently evaluated in a case-control study of 99 CRC patients, 196 patients with adenomas and 696 individuals without neoplastic bowel lesions.

RESULTS: Using logistic regression, we found that CL-L1, M-ficolin and MAp44 levels could significantly distinguish between patients with CRC, patients with adenomas and individuals without neoplastic bowel lesions. Higher levels of CL-L1 or MAp44 were associated with lower odds of CRC (OR 0.42 (0.25-0.70) p = 0.0003 and OR 0.39 (0.23-0.65) p = 0.0003, respectively), whereas higher levels of M-ficolin were associated with higher odds of CRC compared to individuals without CRC (OR 1.94 (1.46-2.59) p < 0.0001). The combination of CL-L1, M-ficolin and MAp44 in a test of CRC versus individuals without CRC resulted in 36 % sensitivity at 83 % specificity.

CONCLUSION: CL-L1, M-ficolin and MAp44 in combination discriminate between CRC and patients without cancer. The markers did not have sufficient discriminatory value for CRC detection, but may prove useful for screening when combined with other markers.

Original languageEnglish
JournalCancer immunology, immunotherapy
Volume64
Issue number1
Pages (from-to)41-50
ISSN0340-7004
DOIs
Publication statusPublished - 2015

ID: 44667098